ReviewArchives of neurology2009
Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies.
Review in Archives of neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- The Antibody Dependant Neurite Outgrowth Modulation Response Involvement in Spinal Cord Injury.Frontiers in immunology · 2022Pooled it
- The Cell-Specific Effects of the Human Remyelination-Promoting rHIgM22 on Sphingolipid Metabolism in Cultured Glial Cells.Neurochemical research · 2026Article
- Selection of DNA Aptamers That Promote Neurite Outgrowth in Human iPSC-Derived Sensory Neuron Organoid Cultures.ACS chemical neuroscience · 2025Article
- Identification of the Lipid Antigens Recognized by rHIgM22, a Remyelination-Promoting Antibody.Neurochemical research · 2023Article
- The Forgotten Brother: The Innate-like B1 Cell in Multiple Sclerosis.Biomedicines · 2022Review
- Autoimmunity: Are we asking the right question?Frontiers in immunology · 2022Article
- Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis.Acta neuropathologica communications · 2020Article
- Current Understanding of Natural Antibodies and Exploring the Possibilities of Modulation Using Veterinary Models. A Review.Frontiers in immunology · 2020Review
- Human Remyelination Promoting Antibody Stimulates Astrocytes Proliferation Through Modulation of the Sphingolipid Rheostat in Primary Rat Mixed Glial Cultures.Neurochemical research · 2019Article
- Human IgM antibody rHIgM22 promotes phagocytic clearance of myelin debris by microglia.Scientific reports · 2018Article
- Natural Autoantibodies: An Undersugn Hero of the Immune System and Autoimmune Disorders-A Point of View.Frontiers in immunology · 2018Article
- Primary Progressive Multiple Sclerosis: Putting Together the Puzzle.Frontiers in neurology · 2017Review
- A monoclonal natural human IgM protects axons in the absence of remyelination.Journal of neuroinflammation · 2016Article
- A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis.Disease models & mechanisms · 2015Article
- A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis.Journal of neuroinflammation · 2015Article
- The role of the immune system in central nervous system plasticity after acute injury.Neuroscience · 2014Review
- The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury.Experimental neurology · 2014Review
- Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations.Degenerative neurological and neuromuscular disease · 2014Review
- B-cell targeting agents in the treatment of multiple sclerosis.Current treatment options in neurology · 2013Article
- Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.Autoimmunity · 2012Review
Corrections and comments
- Erratum issuedEdberg, Dale E [corrected to Edberg, Dale D]
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Natural autoreactive monoclonal IgM antibodies have demonstrated potential as therapeutic agents for central nervous system (CNS) disease. These antibodies bind surface antigens on specific CNS cells, activating intracellular repair-promoting signals. IgM antibodies that bind to surface antigens on oligodendrocytes enhanced remyelination in animal models of multiple sclerosis. IgM antibodies that bind to neurons stimulate neurite outgrowth and prevent neuron apoptosis. The neuron-binding IgM antibodies may have utility in CNS axon- or neuron-damaging diseases, such as amyotrophic lateral sclerosis, stroke, spinal cord injury, or secondary progressive multiple sclerosis. Recombinant remyelination-promoting IgM antibodies have been generated for formal toxicology studies and, after Food and Drug Administration approval, a phase 1 clinical trial. Natural autoreactive monoclonal antibodies directed against CNS cells represent novel therapeutic molecules to induce repair of the nervous system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.